脑栓塞保护装置在主动脉瓣置换手术中对中枢神经系统梗死的影响:一项随机临床试验
该随机临床试验在18个北美中心纳入383例接受主动脉瓣置换(SAVR)的钙化性主动脉瓣狭窄患者,比较两种脑栓塞保护装置与标准主动脉插管对术后7天中枢神经系统梗死的影响。结果显示,吸引式提取装置组和主动脉内过滤装置组与对照组相比,7天中枢神经系统梗死无显著差异,但过滤装置组急性肾损伤和心律失常事件显著增多。
要点
- 在SAVR患者中,脑栓塞保护装置与标准主动脉插管相比未显著降低7天中枢神经系统梗死风险。
- 主动脉内过滤装置组较对照组急性肾损伤事件(14 vs 4,P=0.02)和心律失常(57 vs 30,P=0.004)显著增多。
- 作者认为,降低谵妄、认知功能和症状性卒中的潜在获益需更大规模、更长随访的试验验证。
核心结论
- 在接受SAVR的患者中,与标准主动脉插管相比,脑栓塞保护装置未显著降低7天中枢神经系统梗死风险。
- 作者认为,降低谵妄、认知功能和症状性卒中的潜在获益需更大规模、更长随访的试验验证。
研究设计与样本
- 随机临床试验,于2015年3月至2016年7月在18个北美中心纳入接受SAVR的钙化性主动脉瓣狭窄患者,随访截止至2016年12月。
- 共383例随机患者(平均年龄73.9岁,女性38.4%,368例[96.1%]完成试验),分为吸引式提取装置组(n=118)、主动脉内过滤装置组(n=133)和标准主动脉插管对照组(n=132)。
主要发现
- 术后7天无中枢神经系统梗死率:吸引式提取组32.0% vs 对照组33.3%(组间差异-1.3%,95%CI -13.8%至11.2%);主动脉内过滤组25.6% vs 对照组32.4%(组间差异-6.9%,95%CI -17.9%至4.2%)。
- 30天复合终点:吸引式提取组21.4% vs 对照组24.2%(组间差异-2.8%,95%CI -13.5%至7.9%);主动脉内过滤组33.3% vs 对照组23.7%(组间差异9.7%,95%CI -1.2%至20.5%),均无显著差异。
- 死亡率:吸引式提取组3.4% vs 对照组1.7%;主动脉内过滤组2.3% vs 对照组1.5%;临床卒中:吸引式提取组5.1% vs 对照组5.8%;主动脉内过滤组8.3% vs 对照组6.1%,均无显著差异。
- 术后第7天谵妄:吸引式提取组6.3% vs 对照组15.3%(组间差异-9.1%,95%CI -17.1%至-1.0%);主动脉内过滤组8.1% vs 对照组15.6%(组间差异-7.4%,95%CI -15.5%至0.6%)。
- 主动脉内过滤组较对照组急性肾损伤事件(14 vs 4,P=0.02)和心律失常(57 vs 30,P=0.004)显著增多;90天死亡率和总体严重不良事件各组间无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者在结论中指出,潜在获益需更大规模、更长随访的试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Stroke is a major complication of surgical aortic valve replacement (SAVR). OBJECTIVE: To determine the efficacy and adverse effects of cerebral embolic protection devices in reducing ischemic central nervous system (CNS) injury during SAVR. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial of patients with calcific aortic stenosis undergoing SAVR at 18 North American centers between March 2015 and July 2016. The end of follow-up was December 2016. INTERVENTIONS: Use of 1 of 2 cerebral embolic protection devices (n = 118 for suction-based extraction and n = 133 for intra-aortic filtration device) vs a standard aortic cannula (control; n = 132) at the time of SAVR. MAIN OUTCOMES AND MEASURES: The primary end point was freedom from clinical or radiographic CNS infarction at 7 days (± 3 days) after the procedure. Secondary end points included a composite of mortality, clinical ischemic stroke, and acute kidney injury within 30 days after surgery; delirium; mortality; serious adverse events; and neurocognition. RESULTS: Among 383 randomized patients (mean age, 73.9 years; 38.4% women; 368 [96.1%] completed the trial), the rate of freedom from CNS infarction at 7 days was 32.0% with suction-based extraction vs 33.3% with control (between-group difference, -1.3%; 95% CI, -13.8% to 11.2%) and 25.6% with intra-aortic filtration vs 32.4% with control (between-group difference, -6.9%; 95% CI, -17.9% to 4.2%). The 30-day composite end point was not significantly different between suction-based extraction and control (21.4% vs 24.2%, respectively; between-group difference, -2.8% [95% CI, -13.5% to 7.9%]) nor between intra-aortic filtration and control (33.3% vs 23.7%; between-group difference, 9.7% [95% CI, -1.2% to 20.5%]). There were no significant differences in mortality (3.4% for suction-based extraction vs 1.7% for control; and 2.3% for intra-aortic filtration vs 1.5% for control) or clinical stroke (5.1% for suction-based extraction vs 5.8% for control; and 8.3% for intra-aortic filtration vs 6.1% for control). Delirium at postoperative day 7 was 6.3% for suction-based extraction vs 15.3% for control (between-group difference, -9.1%; 95% CI, -17.1% to -1.0%) and 8.1% for intra-aortic filtration vs 15.6% for control (between-group difference, -7.4%; 95% CI, -15.5% to 0.6%). Mortality and overall serious adverse events at 90 days were not significantly different across groups. Patients in the intra-aortic filtration group vs patients in the control group experienced significantly more acute kidney injury events (14 vs 4, respectively; P = .02) and cardiac arrhythmias (57 vs 30; P = .004). CONCLUSIONS AND RELEVANCE: Among patients undergoing SAVR, cerebral embolic protection devices compared with a standard aortic cannula did not significantly reduce the risk of CNS infarction at 7 days. Potential benefits for reduction in delirium, cognition, and symptomatic stroke merit larger trials with longer follow-up. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02389894.
引用
- Mack MJ, Acker MA, Gelijns AC, et al. Effect of Cerebral Embolic Protection Devices on CNS Infarction in Surgical Aortic Valve Replacement: A Randomized Clinical Trial. JAMA. 2017. PMID: 28787505. doi:10.1001/jama.2017.9479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。